Cargando…

Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds

BACKGROUND: Neolaxiflorin B is derived from ent-kaurane like laxiflorin J and eriocalyxin B with a relatively low potency as an antitumor agent. During preliminary structure–activity relationship studies, the α,β-unsaturated ketone (enone) system is an important active group. METHODS: Seven neolaxif...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing-Ping, Xiao, Ye-Zhi, Hu, Yu, Li, Xiao-Nian, Wu, Ming-Jiang, Zhao, Yong, Zhao, Yan, Ma, Ze-Jin, Shen, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712212/
https://www.ncbi.nlm.nih.gov/pubmed/31692523
http://dx.doi.org/10.2147/DDDT.S202345
_version_ 1783446635472224256
author Liu, Jing-Ping
Xiao, Ye-Zhi
Hu, Yu
Li, Xiao-Nian
Wu, Ming-Jiang
Zhao, Yong
Zhao, Yan
Ma, Ze-Jin
Shen, Jing
author_facet Liu, Jing-Ping
Xiao, Ye-Zhi
Hu, Yu
Li, Xiao-Nian
Wu, Ming-Jiang
Zhao, Yong
Zhao, Yan
Ma, Ze-Jin
Shen, Jing
author_sort Liu, Jing-Ping
collection PubMed
description BACKGROUND: Neolaxiflorin B is derived from ent-kaurane like laxiflorin J and eriocalyxin B with a relatively low potency as an antitumor agent. During preliminary structure–activity relationship studies, the α,β-unsaturated ketone (enone) system is an important active group. METHODS: Seven neolaxiflorin B derivatives containing α,β-unsaturated ketone moieties were synthesized. In vitro, activity was evaluated against three human tumor cell lines and a rat myogenic cell line (HepG2, NSCLC-H292, SNU-1040, and L6, respectively) by MTT assay. RESULTS: Compound 15 appeared a promising antitumor lead due to its cytotoxic potency and relatively high selectivity, with an SI value of 13.14. Flow cytometry analysis was conducted to show that NSCLC-H292 cells were blocked in the G0/G1 phase in the presence of compound 15, thus inhibiting the proliferation of tumor cells. CONCLUSION: This study has revealed that compound 15 is a promising antitumor lead due to the cytotoxic potencies and the high selectivity it displayed when compared to natural counterparts.
format Online
Article
Text
id pubmed-6712212
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67122122019-11-05 Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds Liu, Jing-Ping Xiao, Ye-Zhi Hu, Yu Li, Xiao-Nian Wu, Ming-Jiang Zhao, Yong Zhao, Yan Ma, Ze-Jin Shen, Jing Drug Des Devel Ther Original Research BACKGROUND: Neolaxiflorin B is derived from ent-kaurane like laxiflorin J and eriocalyxin B with a relatively low potency as an antitumor agent. During preliminary structure–activity relationship studies, the α,β-unsaturated ketone (enone) system is an important active group. METHODS: Seven neolaxiflorin B derivatives containing α,β-unsaturated ketone moieties were synthesized. In vitro, activity was evaluated against three human tumor cell lines and a rat myogenic cell line (HepG2, NSCLC-H292, SNU-1040, and L6, respectively) by MTT assay. RESULTS: Compound 15 appeared a promising antitumor lead due to its cytotoxic potency and relatively high selectivity, with an SI value of 13.14. Flow cytometry analysis was conducted to show that NSCLC-H292 cells were blocked in the G0/G1 phase in the presence of compound 15, thus inhibiting the proliferation of tumor cells. CONCLUSION: This study has revealed that compound 15 is a promising antitumor lead due to the cytotoxic potencies and the high selectivity it displayed when compared to natural counterparts. Dove 2019-08-23 /pmc/articles/PMC6712212/ /pubmed/31692523 http://dx.doi.org/10.2147/DDDT.S202345 Text en © 2019 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Jing-Ping
Xiao, Ye-Zhi
Hu, Yu
Li, Xiao-Nian
Wu, Ming-Jiang
Zhao, Yong
Zhao, Yan
Ma, Ze-Jin
Shen, Jing
Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds
title Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds
title_full Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds
title_fullStr Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds
title_full_unstemmed Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds
title_short Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds
title_sort synthesis and antitumor evaluation of neolaxiflorin b inspired compounds
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712212/
https://www.ncbi.nlm.nih.gov/pubmed/31692523
http://dx.doi.org/10.2147/DDDT.S202345
work_keys_str_mv AT liujingping synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT xiaoyezhi synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT huyu synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT lixiaonian synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT wumingjiang synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT zhaoyong synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT zhaoyan synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT mazejin synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds
AT shenjing synthesisandantitumorevaluationofneolaxiflorinbinspiredcompounds